Keros Therapeutics (KROS) Return on Equity: 2019-2025
Historic Return on Equity for Keros Therapeutics (KROS) over the last 6 years, with Sep 2025 value amounting to 0.09%.
- Keros Therapeutics' Return on Equity rose 49.00% to 0.09% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.09%, marking a year-over-year increase of 49.00%. This contributed to the annual value of -0.41% for FY2024, which is 9.00% up from last year.
- Latest data reveals that Keros Therapeutics reported Return on Equity of 0.09% as of Q3 2025, which was up 249.46% from 0.03% recorded in Q2 2025.
- Keros Therapeutics' 5-year Return on Equity high stood at 0.09% for Q3 2025, and its period low was -0.54% during Q4 2023.
- Its 3-year average for Return on Equity is -0.30%, with a median of -0.39% in 2023.
- Per our database at Business Quant, Keros Therapeutics' Return on Equity crashed by 114bps in 2021 and then skyrocketed by 49bps in 2025.
- Keros Therapeutics' Return on Equity (Quarterly) stood at -0.25% in 2021, then fell by 15bps to -0.40% in 2022, then fell by 14bps to -0.54% in 2023, then rose by 20bps to -0.34% in 2024, then soared by 49bps to 0.09% in 2025.
- Its Return on Equity stands at 0.09% for Q3 2025, versus 0.03% for Q2 2025 and 0.01% for Q1 2025.